Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDO-JAK
2025-520757-36-00Phase 4Authorised
- Sponsor
- Sint Maartenskliniek
- Start
- Jul 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tofacitinib, baricitinib, filgotinib and upadacitinib in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) (2 arms), sponsored by Sint Maartenskliniek. Planned start Jul 2025; status: authorised.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2025-520757-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520757-36-00.